Basic Uroxatral Information

• INN (International Nonproprietary Name): Alfuzosin
• Brand Names Available In Canada (English): Uroxatral; Xatral; Alfuzosin Teva; Alfuzosin Mylan; Alfuzosin Sandoz
• ATC Code: G04CA01
• Forms & Dosages: Extended‑release tablet, typically 10 mg once daily after the same meal each day
• Manufacturers In Canada (English): Health Canada–authorised suppliers include originator listings by Sanofi and generic suppliers such as Teva, Sandoz, and Mylan (availability varies by distributor)
• Registration Status In Canada (English): Health Canada‑authorised
• OTC / Rx Classification: Prescription‑only (Rx)

Latest Research Highlights (Canada & International, 2022–2025)

Patients ask: "How fast will my flow improve and is it safe?"

Randomized controlled trials and observational reports from 2022–2024 show that alfuzosin extended‑release 10 mg once daily provides clinically meaningful relief of lower urinary tract symptoms (LUTS) and improves peak urinary flow (Qmax) within one to four weeks.

Meta‑analyses comparing alpha‑1 blockers find alfuzosin’s symptom relief broadly similar to tamsulosin and silodosin, with differences in side‑effect profiles linked to receptor selectivity.

Post‑marketing safety reviews emphasise early hypotension and syncope risk and note intraoperative floppy iris syndrome (IFIS) as a cataract‑surgery safety consideration.

Canadian observational data are more limited than international trials, but available reports align with global findings and Health Canada product monographs mirror FDA and EMA guidance.

Practical dosing and formulation matter: the extended‑release 10 mg tablet taken after the same meal optimises absorption and reduces hypotensive peaks compared with irregular timing.

Adverse Event Highlights: Dizziness and headache are among the most common events (dizziness reported ≥1%).

Serious events such as syncope and severe hypotension are uncommon but important to monitor, especially during the first dose or when combined with antihypertensives.

Follow‑up is essential: reassess symptoms and blood pressure within the first one to four weeks after starting therapy.

Clinical Effectiveness In Canada

Patients wonder: "Does alfuzosin work the same here as in the trials?"

Health Canada‑authorised alfuzosin extended‑release aligns with international claims for treating BPH in adult males.

Canadian urology guidelines and provincial formularies list alpha‑blockers as first‑line symptomatic therapy, and alfuzosin is included among available options when clinically indicated.

Real‑world prescribing in Canada favours cost‑effective generics, while brand availability (Uroxatral versus generics) varies by pharmacy chain and region.

Health Canada product information emphasises the 10 mg once‑daily dose taken after the same meal, contraindication in moderate–severe hepatic impairment, and interactions with strong CYP3A4 inhibitors.

IPSS

International Prostate Symptom Score, a standard symptom questionnaire.

Qmax

Peak urinary flow rate measured in mL/s.

DIN

Drug Identification Number used in Canadian listings; check official provincial formularies for exact DINs.

Access routes include family physicians and urologists, with rural telehealth and pharmacy counselling helping with follow‑up.

Indications And Expanded Uses (Approved Versus Off‑Label In Canada)

Men commonly ask: "What exactly will this medicine treat?"

• Approved Use: Symptomatic relief of LUTS due to benign prostatic hyperplasia (BPH) in adult males with alfuzosin extended‑release 10 mg once daily.
• Not Approved: Use in women or children is not authorised.
• Off‑Label Considerations: Occasional specialist use for bladder outlet obstruction from other causes, but evidence is limited and specialist guidance is recommended.

Patients should expect symptom control rather than prostate shrinkage, and timelines for reassessment should be set at about 1–3 months or sooner if side effects occur.

Bilingual counselling and shared decision‑making align with Canadian informed‑consent values.

Composition And Brand Landscape In Canada

People ask: "Which brands and generics will I see on the shelf?"

The INN is alfuzosin (alfuzosinum in international term usage).

International brands include Uroxatral and Xatral, while generics from Teva, Mylan, and Sandoz are common in many markets.

In Canada, Health Canada authorisation exists and distribution mixes originator and generic suppliers depending on regional availability.

Packaging is generally extended‑release 10 mg tablets in blister packs or bottles.

• Local distributors and pharmacy chains: Shoppers Drug Mart, Rexall, Jean Coutu, London Drugs (availability varies by region).
• Storage: store at room temperature 20–25°C and keep in original packaging.
• Substitution: pharmacists may substitute generics under provincial rules; patients should confirm with their pharmacist.

Contraindications And Special Precautions

Patients often worry: "Who should not take this medicine?"

Absolute contraindications include moderate to severe hepatic insufficiency and known hypersensitivity to alfuzosin or excipients.

Use is contraindicated with strong CYP3A4 inhibitors such as ketoconazole.

Cautions include severe renal impairment, history of orthostatic hypotension, concurrent antihypertensives, and perioperative cataract patients because of IFIS risk.

Absolute Contraindication

Conditions where the drug should not be used because of clear harm or lack of data.

Relative Contraindication

Situations requiring clinical judgement and monitoring before use.

Data Box: IFIS has been reported with alpha‑blockers and should be flagged to ophthalmology before cataract surgery.

Pharmacists should prioritise medication reconciliation at transitions of care, and screen for diabetes and cardiovascular disease in Indigenous and remote communities where comorbidity is more prevalent.

Counselling points include rising slowly from sitting and avoiding driving until the individual knows how the medicine affects them.

Dosage Guidelines (Canadian Practice & Adjustments)

Typical patient question: "How do I take Uroxatral and what if I miss a dose?"

Standard adult dosing is one 10 mg extended‑release tablet once daily after the same meal each day.

No routine dose adjustment is required for elderly patients, but clinicians should watch for increased sensitivity to hypotension.

Mild to moderate renal impairment usually requires no initial adjustment; avoid use in severe renal insufficiency without specialist input.

Alfuzosin is contraindicated in moderate to severe hepatic impairment.

• Start: 10 mg ER once daily after the same meal.
• Monitor: Blood pressure and dizziness within first 1–2 weeks.
• Adjust: Consult specialist for severe renal or hepatic disease.

Missed dose: take as soon as remembered unless it is almost time for the next dose; do not double up.

Overdose: may cause profound hypotension; seek emergency medical care and provide supportive treatment.

Pharmacists should verify provincial coverage (ODB, PharmaCare, RAMQ) and check DINs when dispensing.

Patient counselling: take after the same meal each day, report dizziness or fainting immediately, and use telepharmacy follow‑up if remote.

Interactions Overview (Food, Drugs, Canadian Lifestyle)

Common patient worry: "Will this clash with my other medicines or wine?"

Alfuzosin is metabolised mainly via CYP3A4, so potent CYP3A4 inhibitors such as ketoconazole and ritonavir increase exposure and are contraindicated.

Concomitant antihypertensives may increase orthostatic hypotension and syncope risk.

Take alfuzosin after the same meal to optimise absorption and reduce hypotensive peaks.

• Key drug interactions: strong CYP3A4 inhibitors (contraindicated), certain protease inhibitors, and other drugs that lower blood pressure.
• Foods/behaviours: alcohol can increase dizziness; avoid heavy drinking during initiation.

Farm and outdoor workers in rural Canada should be counselled on fall risk and scheduling tasks to reduce exposure to heights or heavy machinery during early treatment.

Cultural Perceptions And Patient Habits In Canada

Patients sometimes say: "I want simple once‑daily pills and straight answers."

Canadian patient forums and provincial health portals emphasise rapid symptom relief, a preference for once‑daily regimens, and concern about dizziness and sexual side effects.

Trust in pharmacists and family physicians is high, and many patients expect bilingual English/French information.

Rural patients report limited urology access and rely on telehealth and pharmacy counselling to bridge gaps.

Cost perceptions vary; Canadians expect broad coverage but encounter copays and formulary restrictions across provinces.

• Patient concerns: dizziness, interactions with blood pressure medications, and cataract surgery planning.
• Advice: normalise urinary symptom conversations and bring full medication lists to visits.

Cultural sensitivity is important when counselling Indigenous patients and newcomers; offer bilingual resources and involve caregivers when appropriate.

Availability And Pricing Patterns (Canadian Pharmacies & Cross‑Border Notes)

Typical question: "Where can I get Uroxatral and how much will it cost?"

Alfuzosin products are prescription‑only and available in brand and generic forms across Canada, with availability varying by chain and region.

Provincial drug plans have differing listing and reimbursement rules, so coverage and copays vary by province and by DIN.

Online Canadian pharmacies can supply prescription medicines with a valid prescription and offer discreet delivery options.

In our online pharmacy, uroxatral is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Cost drivers include brand versus generic, pack size, and provincial formulary status.

Patients should beware of mail‑order imports without a Canadian DIN and always check provincial coverage before ordering large supplies.

Comparable Medicines And Patient Preferences

Many men ask: "Should I take alfuzosin or tamsulosin?"

Competitors include alpha‑blockers such as tamsulosin, terazosin, and doxazosin, and prostate‑reducing agents such as finasteride and dutasteride.

Alpha‑1A selective agents like tamsulosin and silodosin may have different ejaculatory or orthostatic profiles compared with alfuzosin.

Treatment choice depends on comorbid hypertension, sexual side‑effects, and drug interactions; Canadian guidelines recommend tailoring therapy to patient priorities.

• Pros/Cons Checklist For Alfuzosin Versus Tamsulosin:
• Pros: Once‑daily ER formulation, rapid symptom relief.
• Cons: Possible dizziness, hypotension, and IFIS risk; drug interactions via CYP3A4.

Discuss speed of symptom relief versus prostate‑reducing agents and weigh sexual side effects and cardiovascular risks with your prescriber.

Frequently Asked Questions

• Q: How quickly will Uroxatral relieve my symptoms?
  A: Many men notice improvement within days to weeks; reassess with your prescriber using IPSS and flow measures.
• Q: Is it safe with my blood pressure pills?
  A: Use caution — combined therapy can cause dizziness or syncope; your prescriber or pharmacist may stagger timing or monitor blood pressure more closely.
• Q: Can I drive after starting alfuzosin?
  A: Wait until you know how it affects you; avoid driving if you feel dizzy or faint.
• Q: Will it shrink my prostate?
  A: No — alfuzosin relaxes smooth muscle to relieve symptoms but does not reduce prostate size; 5‑ARIs are used to shrink the gland.
• Q: Is it covered by my provincial plan?
  A: Coverage varies; check ODB, BC PharmaCare, or RAMQ listings and confirm the drug’s DIN with your pharmacist.

Guidelines For Proper Use (Pharmacist & Provincial Tips)

Pharmacists ask: "What should be documented and how should follow‑up proceed?"

• Pharmacist Checklist:
• Confirm dose: 10 mg ER once daily after the same meal.
• Review full medication list for CYP3A4 inhibitors and antihypertensives.
• Document allergies, hepatic and renal history, and planned ophthalmic surgery.
• Provide counselling on hypotension precautions and signs of IFIS to patients and surgical teams.

Suggested follow‑up protocol:

Start → Monitor Week 1 (BP/dizziness) → Reassess Month 1 (symptoms and tolerability) → Ongoing visits as indicated.

Hospitals and clinics should flag alfuzosin on pre‑op medication lists so ophthalmologists are aware of IFIS risk.

Provide a bilingual two‑column (EN/FR) patient handout when possible, and consider caregiver education and fall‑prevention measures for elderly or remote patients.

Delivery Across Canada (English)